SubsidieMeestersDevelopment of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
Projectdetails
Introduction
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation.
Product Overview
Our compound PBF-680 is a first-in-class therapy with disease-modifying effects in respiratory diseases like COPD.
Market Need
- Over 65 million patients suffer from COPD.
- There are no approved therapies that target disease progression.
Mechanism of Action
PBF-680 is a unique molecule designed to specifically antagonize the Adenosine 1 Receptor (A1R).
Clinical Trials
- It has shown to be safe and well-tolerated in phase 1 trials.
- Demonstrated to reduce pulmonary symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials.
Future Plans
With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need.
Funding Goals
Proven clinical efficacy will be the major milestone to raise €30M (including €15M EIC Equity) for a phase 3 trial, followed by an additional fundraising or IPO to independently reach market launch with PBF-680.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.476.106 |
| Totale projectbegroting | € 3.537.295 |
Tijdlijn
| Startdatum | 1-1-2022 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- PALO BIOFARMA SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Preclinical development of new nucleoside-based drug against leukemiaThe project aims to develop Carbacitabin (CAB) as a stable, effective treatment for high-risk leukemia patients through preclinical optimization, safety studies, and commercial preparation. | ERC POC | € 150.000 | 2024 | Details |
Diagnostische beeldvorming van vroege longfibroseBiOrion ontwikkelt een haalbaarheidsplan voor het gebruik van PET-tracers bij longfibrose om investeerders te werven en de klinische ontwikkeling te financieren. | MIT Haalbaarheid | € 14.426 | 2022 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
Preclinical development of new nucleoside-based drug against leukemia
The project aims to develop Carbacitabin (CAB) as a stable, effective treatment for high-risk leukemia patients through preclinical optimization, safety studies, and commercial preparation.
Diagnostische beeldvorming van vroege longfibrose
BiOrion ontwikkelt een haalbaarheidsplan voor het gebruik van PET-tracers bij longfibrose om investeerders te werven en de klinische ontwikkeling te financieren.